Kallman syndrome: Difference between revisions

Jump to navigation Jump to search
Line 16: Line 16:
{{CMG}}
{{CMG}}


==Diagnosis==
The diagnosis is often one of exclusion found during the workup of delayed puberty. The presence of anosmia together with delayed puberty in either boys or girls should suggest Kallmann syndrome.


==Treatment==
==Treatment==

Revision as of 16:28, 19 September 2012

Kallman syndrome
The structure of GNRH1
(from PDB: 1YY1​)
ICD-10 E23.0
ICD-9 253.4
OMIM 308700 147950 244200 138850 607002
DiseasesDB 7091
MeSH D017436

Kallman syndrome Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Kallman Syndrome from other Diseases

Epidemiology and Demographics

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

CT

MRI

Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Prevention

Social Impact

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Kallman syndrome On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Kallman syndrome

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Kallman syndrome

CDC on Kallman syndrome

Kallman syndrome in the news

Blogs on Kallman syndrome

Directions to Hospitals Treating Kallman syndrome

Risk calculators and risk factors for Kallman syndrome

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Treatment

Treatment is directed at restoring the deficient hormones -- known as hormone therapy (HT). Males are administered human chorionic gonadotropin (hCG) or testosterone. Females are treated with oestrogen and progestins.

To induce fertility in males or females, GnRH (aka LHRH) is administered by an infusion pump, or hCG/hMG/FSH/LH combinations are administered through regular injections. Fertility is only maintained whilst actually being treated with these hormones. Once fertility treatment stops it is necessary to revert to the normal HRT of testosterone for men and oestrogen + progestins for women.

The main health risk, for both men and women, of untreated Kallmann Syndrome is osteoporosis. Therefore, regular bone density scans (every 2 years or so) are advisable, even if being treated with HRT. Additional medication specifically for osteoporosis is necessary in some cases.

Epidemiology

Kallmann syndrome occurs at a rate of 1 in 10,000 male births and 1 in 50,000 female births. It may be inherited as an X-linked condition, an autosomal dominant condition or as an autosomal recessive condition. Statistics are sparse, but it seems that autosomal dominant is the most common form of heredity.

One recent paper [1] quoted an incidence in males of 0.025%, or 1 in 4,000, with the female incidence being 3 to 5 times less.

Even though mutations in the KAL-1 gene on the X chromosome can cause Kallmann syndrome, only 11-14% of patients with Kallmann syndrome have detectable KAL-1 mutations.

Autosomal dominant mutations have been described with the FGFR-1 (8p12) gene, sometimes referred to as the KAL-2 gene. This is thought to cause about 10% of cases. However, the majority of KS cases (70%) would seem to be the result of autosomal dominant genes even though the identity of those genes is not yet known.

Autosomal recessive mutations of the GnRH receptor gene (4q13.2) have also been reported.[1] This defect appears to produce a wider spectrum of physical symptoms than with the other gene defects, and the defect lies in the ability of the pituitary gland to recognize GnRH, rather than the ability of the hypothalamus to produce GnRH. It is debatable as to whether this is in fact Kallmann syndrome since the GnRH receptor development is not related to anosmia.

There may also be no obvious family history of inheritance (sporadic cases). However, it is possible for Kallmann syndrome genes to be passed on to children of a sporadic case.

Psychological Issues

In some cases, the psychological effects of having this condition can outweigh the significance of any physical symptoms.

The social stigma of being left behind by your peer group at a vital stage of physical and emotional development can leave lasting damage to some people. Some people with Kallmann syndrome find it difficult to fit into social groups and may have trouble in forming relationships both on the physical and emotional level. This might be more profound in people who are diagnosed later in life.

Practical Issues

While the lack of sense of smell may not be important when compared to the lack of sexual development, it does give rise to a few situations where care should be taken. These can include:

Personal hygiene.

Gas leaks within the home. Fitting gas detectors within the home is recommended.

Food & drink spoilage. Extra care should be taken with the expiration dates for food and drink.

References

  1. 1.0 1.1 Quinton R. Topical Endocrinology 22. (15-20)

External links

Template:Skin and subcutaneous tissue symptoms and signs Template:Nervous and musculoskeletal system symptoms and signs Template:Urinary system symptoms and signs Template:Cognition, perception, emotional state and behaviour symptoms and signs Template:Speech and voice symptoms and signs Template:General symptoms and signs

de:Kallmann-Syndrom it:Sindrome di Kallmann he:תסמונת קלמן nl:Syndroom van Kallmann fi:Kallmannin oireyhtymä


Template:WikiDoc Sources